Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Transcript
The next question that I’m often asked is: when a patient has a central tumor, a tumor that’s down the central airway to the lung at the base of the lung, historically that would require one to take the entire lung out or do a pneumonectomy. What we’ve realized is that when you do that, you may take that area with the mass out, but you’re also taking out a significant amount of normal lung and causing a good bit of morbidity to that patient. So we have found that if the tumor is only locally invasive to the central airway, you can cut that airway above and below where the mass is and sew the other parts of the lung back together and actually save the remainder of the lung and I probably do 20 or more of these a year, I’m one of the busier surgeons in the country that does sleeve resections, and they’re really, really useful.
Generally when the patient has a tumor that has grown out of one of their airways, that part of the lung is not functioning. If that’s all that we take out, then we actually leave them all of their functional lung, and the sleeve resections have been very helpful in patients who might otherwise be considered marginal for surgery. If you’re not taking anything out that’s functioning, you can actually take them though the operation very safely.
It does require them to participate in their care more than some of the other surgical procedures, and what I mean by that is that I tell all my patients after the sleeve, on the area where I’ve sewn the two pipes or the airways back together, secretions like to stick there, and so after surgery they have to get up, move around, cough, and deep breathe so that they can keep those areas open. Otherwise, their post-operative care is pretty much the same as any other patient, and their recuperation is very similar as well. I have found this to be quite useful in helping patients remove large tumors that are central then, but you can salvage a lot of the other airway. I generally draw pictures to display this so they can see exactly what part of the lung we’re taking out and what part that we’re sewing back together.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: